Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.
暂无分享,去创建一个
Shigemi Matsumoto | Takashi Ninomiya | Shuta Tomida | Marc Ladanyi | Hiromasa Yamamoto | M. Ladanyi | M. Kris | S. Toyooka | K. Kiura | S. Tomida | K. Suzawa | Bob T. Li | M. Muto | M. Kanai | Shinichi Toyooka | Mark G Kris | Katsuyuki Kiura | Manabu Muto | Bob T Li | S. Matsumoto | Masashi Kanai | Ken Suzawa | Patrice Desmeules | T. Ninomiya | P. Desmeules | H. Yamamoto
[1] Jana Marie Schwarz,et al. MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.
[2] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[3] David Haussler,et al. New Methods for Detecting Lineage-Specific Selection , 2006, RECOMB.
[4] J. Soh,et al. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations , 2015, Cancer Science.
[5] X. Puente,et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. , 2013, Cancer discovery.
[6] Wendy Winckler,et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.
[7] Bin Li,et al. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients , 2015, Oncotarget.
[8] Y. Okuno,et al. The possibility of clinical sequencing in the management of cancer. , 2016, Japanese journal of clinical oncology.
[9] Carlos L Arteaga,et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.
[10] Justin C. Fay,et al. Identification of deleterious mutations within three human genomes. , 2009, Genome research.
[11] J. Soh,et al. Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas , 2013, Journal of the National Cancer Institute.
[12] Vamsidhar Velcheti,et al. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[14] O. Bocharova,et al. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. , 2010, Journal of molecular biology.
[15] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[16] Hiromasa Yamamoto,et al. Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway , 2016, Scientific Reports.
[17] K. Kiura,et al. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience , 2016, Cancer Chemotherapy and Pharmacology.
[18] Roman G. Efremov,et al. Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State* , 2008, Journal of Biological Chemistry.